Resorbable Magnesium Scaffolds Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Magmaris, Freesolve.
- Who it may be relevant to
- Registry conditions: Coronary Artery Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Australia, Germany, Italy, Latvia, Poland +2
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
RMS (Resorbable Magnesium Scaffolds) Registry
Overview
The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Interventions
- Device Magmaris
MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length. - Device Freesolve
Freesolve is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Primary outcome measures
- Target Lesion Failure (TLF) [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- According to the IFU
Exclusion criteria
- According to the IFU
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Germany · 5 centers
- Heart Center Segeberger Kliniken — Bad Segeberg
- Krankenhaus Buchholz — Buchholz
- Klinikum Westfalen, Knappschaft KH — Dortmund
- Klinikum Herford — Herford
- Herz-und Gefäßzentrum Oberallgäu-Kempten — Kempten
Switzerland · 3 centers
- Lindenhofspital — Bern
- Centre Hospitalier Universitaire Vaudois — Lausanne
- Solothurner Spitäler AG — Olten
Australia · 1 center
- Cairns Hospital — Cairns
Italy · 1 center
- Centro Cardiologico Monzino — Milan
Latvia · 1 center
- Daugavpils Regional Hospital — Daugavpils
Poland · 1 center
- 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ w Lublinie — Lublin
Slovakia · 1 center
- SUSCCH Banska Bystrica — Banská Bystrica
Publications
- Wolbert S, Schmidt T, Wittek F, Mayer B, Raake P, Bongiovanni D, Torzewski J. One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions. Front Cardiovasc Med. 2026 Jun 12;13:1854686. doi: 10.3389/fcvm.2026.1854686. eCollection 2026. PMID 42368841
Identifiers
NCT: NCT04679740 · C1908